In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).
A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan
French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung
Signs that the Federal Trade Commission (FTC) in the US may be softening its stance on pharma deals seem to have been misread, as the regulator has now sued to block Sanof
Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo